论文部分内容阅读
子宫内膜腺癌占所有妇科恶性肿瘤的35—40%。据世界各地47个医疗机构1962—1968年14836例子宫内膜腺癌汇集,Ⅰ期(根据FIGO 分期,以下同)占73.8%,Ⅱ期占13.6%,Ⅲ期、Ⅳ期只占12%。可见,本病大多能早期发现。重要的问题是如何提高五年生存率。把放疗和手术密切配合已成为放疗科医生和妇科肿瘤医生日益关注的课题。手术仍是子宫内膜腺癌最重要的治疗方法,但只用一种治疗手段便可获较好效果的想法曾严重阻碍了子宫内膜腺癌治疗的进展。随着放射生物学和放射物理学日新月
Endometrial adenocarcinoma accounts for 35-40% of all gynecological malignancies. According to 4736 medical institutions worldwide, 14836 cases of endometrial adenocarcinoma were collected from 1962 to 1968. Stage Ⅰ (according to FIGO staging, the same below) accounted for 73.8%, stage Ⅱ 13.6%, stage Ⅲ, stage IV only 12%. Visible, most of the early detection of the disease. The important question is how to improve the five-year survival rate. Radiotherapy and surgery in close cooperation has become a radiotherapy surgeon and gynecologic oncology doctor increasingly concerned about the issue. Surgery is still the most important treatment for endometrial adenocarcinoma, but the idea that only one treatment can achieve better results has seriously hampered the progress of endometrial adenocarcinoma therapy. With the advent of radiobiology and radiophysiology